New York – May 19, 2016 – Cooley advised Oncobiologics on its $35 million initial public offering and $5 million concurrent private placement of units (comprised of common stock, Series A warrants and Series B warrants). The company’s units now trade on the NASDAQ Global Market under the symbol “ONSIU,” and following separation of the units, the company’s common stock, Series A warrants and Series B warrants will begin trading under the symbols “ONS,” “ONSIW,” and “ONSIZ,” respectively. Oncobiologics, based in Cranbury, New Jersey, is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics.
The Cooley corporate and securities team included Yvan-Claude Pierre, Daniel Goldberg, Div Gupta, Marianne Sarrazin, Pia Kaur, Sunny Kim, Leah Braukman and Donna Salcedo.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.